1. Anti-infection
    Apoptosis
  2. HSV
    Bacterial
    Apoptosis
    Antibiotic
  3. Acyclovir

Acyclovir (Synonyms: Aciclovir; Acycloguanosine)

Cat. No.: HY-17422 Purity: 99.34%
Handling Instructions

Acyclovir (Aciclovir) is a guanosine analogue and an orally active antiviral agent. Acyclovir inhibits HSV-1 (IC50 of 0.85 μM), HSV-2 (IC50 of 0.86 μM) and varicella-zoster virus. Acyclovir can be phosphorylated by viral thymidine kinase (TK), and Acyclovir triphosphate interferes with viral DNA polymerization through competitive inhibition with guanosine triphosphate and obligatory chain termination. Acyclovir prevents bacterial infections during induction therapy for acute leukaemia.

For research use only. We do not sell to patients.

Acyclovir Chemical Structure

Acyclovir Chemical Structure

CAS No. : 59277-89-3

Size Price Stock Quantity
Free Sample (0.5-1 mg)   Apply Now  
10 mM * 1 mL in DMSO USD 66 In-stock
Estimated Time of Arrival: December 31
50 mg USD 60 In-stock
Estimated Time of Arrival: December 31
100 mg USD 96 In-stock
Estimated Time of Arrival: December 31
500 mg USD 144 In-stock
Estimated Time of Arrival: December 31
1 g   Get quote  
5 g   Get quote  

* Please select Quantity before adding items.

Top Publications Citing Use of Products
  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Acyclovir (Aciclovir) is a guanosine analogue and an orally active antiviral agent. Acyclovir inhibits HSV-1 (IC50 of 0.85 μM), HSV-2 (IC50 of 0.86 μM) and varicella-zoster virus. Acyclovir can be phosphorylated by viral thymidine kinase (TK), and Acyclovir triphosphate interferes with viral DNA polymerization through competitive inhibition with guanosine triphosphate and obligatory chain termination[1][2][3]. Acyclovir prevents bacterial infections during induction therapy for acute leukaemia[4].

IC50 & Target

HSV-1

0.85 μM (IC50)

HSV-2

0.86 μM (IC50)

Bacterial

 

In Vitro

Acyclovir (3-100 µM; 24-72 hours; Jurkat, U937, and K562 leukemia cells) treatment shows a dose- and time-dependent reduction of cell viability[3].
Acyclovir (10-100 µM; 24-72 hours; Jurkat cells) treatment shows a delay/block in S phase and an increase of the sub-G1 peak[3].
Acyclovir (10-100 µM; 24-72 hours; Jurkat cells) treatment activates caspase-3 and presences nuclear DNA fragmentation, thereby indicating apoptotic cell death[3].
In HSV-infected cells, HSV thymidine kinase (HSV-TK) specifically phosphorylate Acyclovir to its monophosphate, and this activation confers a high degree of selectivity of the drugs. Thereafter, the monophosphate is further phosphorylated to the diphosphate (Acyclovir -DP) and triphosphate (Acyclovir -TP) by cellular kinases. The triphosphate is the fully activated metabolite that is toxic to the virus[4].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay[3]

Cell Line: Jurkat, U937, and K562 leukemia cells
Concentration: 3 µM, 10 µM, 30 µM, 100 µM
Incubation Time: 24 hours, 48 hours, and 72 hours
Result: Showed a dose- and time-dependent reduction of cell viability.

Cell Cycle Analysis[3]

Cell Line: Jurkat cells
Concentration: 10 µM, 100 µM
Incubation Time: 24 hours, 48 hours, and 72 hours
Result: Revealed a dose-dependent accumulation of cells in S phase after 24 and 48 h. Showed a dose-dependent increase of the sub-G1 hypodiploid peak after 72 h.

Apoptosis Analysis[3]

Cell Line: Jurkat cells
Concentration: 10 µM, 100 µM
Incubation Time: 24 hours, 48 hours, and 72 hours
Result: Induced cell apoptosis.
In Vivo

Acyclovir (20 mg/kg; oral administration; three times daily; for 10 days; BALB/c mice) treatment in infected mice suppresses the development of skin lesions and results in a dissociation between DTH response and antibody production[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Specific-pathogen-free BALB/c mice (7-week-old) infected with HSV-1[1]
Dosage: 20 mg/kg
Administration: Oral administration; three times daily; for 10 days
Result: Suppressed the development of skin lesions and resulted in a dissociation between DTH response and antibody production.
Clinical Trial
Molecular Weight

225.20

Formula

C₈H₁₁N₅O₃

CAS No.

59277-89-3

SMILES

O=C1NC(N)=NC2=C1N=CN2COCCO

Shipping

Room temperature in continental US; may vary elsewhere.

Storage
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
Solvent & Solubility
In Vitro: 

DMSO : ≥ 50 mg/mL (222.02 mM)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 4.4405 mL 22.2025 mL 44.4050 mL
5 mM 0.8881 mL 4.4405 mL 8.8810 mL
10 mM 0.4440 mL 2.2202 mL 4.4405 mL
*Please refer to the solubility information to select the appropriate solvent.
In Vivo:
  • 1.

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.5 mg/mL (11.10 mM); Clear solution

  • 2.

    Add each solvent one by one:  10% DMSO    90% corn oil

    Solubility: ≥ 2.5 mg/mL (11.10 mM); Clear solution

*All of the co-solvents are provided by MCE.
References

Purity: 99.34%

  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.
  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2

Keywords:

AcyclovirAciclovir AcycloguanosineHSVBacterialApoptosisAntibioticHerpes simplex virusHSV-1HSV-2immunosuppressionantibodythymidinekinaseDNApolymerasetriphosphateanti-herpeticInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

 

Salutation

Applicant Name *

 

Email address *

Phone number *

 

Organization name *

Department *

 

Requested quantity *

Country or Region *

     

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Acyclovir
Cat. No.:
HY-17422
Quantity:
MCE Japan Authorized Agent: